Insmed (INSM) EPS (Weighted Average and Diluted) (2010 - 2026)
Insmed (INSM) recorded quarterly EPS (Weighted Average and Diluted) of -$0.76 in Q1 2026, up 50.33% quarter-over-quarter from -$1.53 in Q4 2025, and up 46.48% on a YoY basis from -$0.52 in Q1 2025.
Insmed (INSM) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Insmed's EPS (Weighted Average and Diluted) history runs 10 years deep, the most recent figure standing at -$0.76 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 46.48% year-over-year to -$0.76; the TTM figure through Mar 2026 stood at -$5.74 (up 3.2% YoY), while the FY2025 annual figure was -$6.42, down 15.26% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.76 for Q1 2026 at Insmed, up from -$1.53 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.76 in Q1 2026 to a low of -$1.94 in Q2 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.29 across 5 years, with a median of -$1.27 in 2024.
- The sharpest annual moves came in 2023 and 2026: EPS (Weighted Average and Diluted) sank 122.5% in 2023, then jumped 46.48% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.23 in 2022, then declined by 4.07% to -$1.28 in 2023, then declined by 1.56% to -$1.3 in 2024, then dropped by 17.69% to -$1.53 in 2025, then soared by 50.33% to -$0.76 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.76 (Q1 2026), -$1.53 (Q4 2025), and -$1.75 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | -0.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.76 |
| Dec 31, 2025 | -1.53 |
| Sep 30, 2025 | -1.75 |
| Jun 30, 2025 | -1.70 |
| Mar 31, 2025 | -1.42 |
| Dec 31, 2024 | -1.30 |
| Sep 30, 2024 | -1.27 |
| Jun 30, 2024 | -1.94 |
| Mar 31, 2024 | -1.06 |
| Dec 31, 2023 | -1.28 |
| Sep 30, 2023 | -1.11 |
| Jun 30, 2023 | -1.78 |
| Mar 31, 2023 | -1.17 |
| Dec 31, 2022 | -1.23 |
| Sep 30, 2022 | -1.09 |
| Jun 30, 2022 | -0.80 |
| Mar 31, 2022 | -0.80 |
| Dec 31, 2021 | -0.95 |
| Sep 30, 2021 | -0.96 |
| Jun 30, 2021 | -1.07 |